Publications
Sara's CureCase Studies
1. A case of clear cell sarcoma-A rare malignancy. Juel J, Ibrahim RM.Int J Surg Case Rep. 2017; PMID: 28587971
2. Clear cell sarcoma of tendons and aponeuroses: a study of 75 patients. Kawai A, Hosono A, Nakayama R, Matsumine A, Matsumoto S, Ueda T, Tsuchiya H, Beppu Y, Morioka H, Yabe H; Japanese Musculoskeletal Oncology Group.Cancer. 2007; PMID: 17133413
3. Primary clear cell sarcoma of humerus: case report. Liu X, Zhang H, Dong Y.World J Surg Oncol. 2011; PMID: 22151733
4. A long-term survivor of clear cell sarcoma-like tumor of the gastrointestinal tract with liver metastasis: a case report. Okada T, Hirano Y, Ishikawa S, Kondo H, Ishii T, Yamaguchi S.Surg Case Rep. 2020. PMID: 33025168
5. Clear cell sarcoma presenting as an interdigital neuroma.Prieskorn DW, et al. Orthop Rev. 1992. PMID: 1523011
6. Clear cell sarcoma of the esophagus: A rare location. Yahyaoui Y, et al. Clin Case Rep. 2019. PMID: 32128181
CCS Characterization
1. Detection and characterization of EWSR1/ATF1 and EWSR1/CREB1 chimeric transcripts in clear cell sarcoma (melanoma of soft parts). Wang WL, Mayordomo E, Zhang W, Hernandez VS, Tuvin D, Garcia L, Lev DC, Lazar AJ, López-Terrada D.Mod Pathol. 2009. PMID: 19561568
1. Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma. Davis IJ, McFadden AW, Zhang Y, Coxon A, Burgess TL, Wagner AJ, Fisher DE. Cancer Res. 2010. PMID: 20068147
CCS of GI Tract
1. Clear cell sarcoma of the gastrointestinal tract presenting as a second malignant neoplasm following neuroblastoma in infancy. Balkaransingh P, Saad SA, Govil SC, Thind PK, Ballance CM, Weiss AR.Pediatr Blood Cancer. 2012. PMID: 21990209
2. Clear cell sarcoma of the stomach. Lagmay JP, et al. Pediatr Blood Cancer. 2009. PMID: 19350639
3. Clear Cell Sarcoma-like Tumor of the Gastrointestinal Tract: Clinical Outcome and Pathologic Features of a Molecularly Characterized Tertiary Center Case Series. Libertini M, Thway K, Noujaim J, Puls F, Messiou C, Fisher C, Jones RL.Anticancer Res. 2018. PMID: 29491075
4. Unusual Clinical Presentation of Gastrointestinal Clear Cell Sarcoma. Raskin GA, Pozharisski KM, Iyevleva AG, Rikov IV, Orlova RV, Imyanitov EN.Gastrointest Tumors. 2015. PMID: 26675070
5. Malignant gastrointestinal neuroectodermal tumor: clinicopathologic, immunohistochemical, ultrastructural, and molecular analysis of 16 cases with a reappraisal of clear cell sarcoma-like tumors of the gastrointestinal tract. Stockman DL, Miettinen M, Suster S, Spagnolo D, Dominguez-Malagon H, Hornick JL, Adsay V, Chou PM, Amanuel B, Vantuinen P, Zambrano EV.Am J Surg Pathol. 2012. PMID: 22592145
6. Clear cell sarcoma-like tumor of the gastrointestinal tract, presenting as a second malignancy after childhood hepatoblastoma. Thway K, Judson I, Fisher C.Case Rep Med. 2014. PMID: 24715928
7. Clear cell sarcoma-like tumor of the gastrointestinal tract: an evolving entity. Wang J, Thway K.Arch Pathol Lab Med. 2015. PMID: 25724038
8. Clear cell sarcoma-like tumor of the gastrointestinal tract: A clinicopathological review. Washimi K, Takagi M, Hisaoka M, Kawachi K, Takeyama M, Hiruma T, Narimatsu H, Yokose T.Pathol Int. 2017. PMID: 2888788
9. Clear cell sarcoma of the gastrointestinal tract after very low-dose therapeutic radiation therapy: a case report. Yang JC, Chou AJ, Oeffinger KC, La Quaglia MP, Wolden SL.J Pediatr Surg. 2012. PMID: 23084213
Clinical Trial Results
1. Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'. Schöffski P, Wozniak A, Stacchiotti S, Rutkowski P, Blay JY, Lindner LH, Strauss SJ, Anthoney A, Duffaud F, Richter S, Grünwald V, Leahy MG, Reichardt P, Sufliarsky J, van der Graaf WT, Sciot R, Debiec-Rychter M, van Cann T, Marréaud S, Lia M, Raveloarivahy T, Collette L, Bauer S.Ann Oncol. 2019. PMID: 29741569
2. Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial. Wagner AJ, Goldberg JM, Dubois SG, Choy E, Rosen L, Pappo A, Geller J, Judson I, Hogg D, Senzer N, Davis IJ, Chai F, Waghorne C, Schwartz B, Demetri GD.Cancer. 2012. PMID: 22605650
General Sarcoma Studies
1. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Van Glabbeke M, Verweij J, Judson I, Nielsen OS; EORTC Soft Tissue and Bone Sarcoma Group.Eur J Cancer. 2002. PMID: 11872347
2. B cells and tertiary lymphoid structures promote immunotherapy response. Helmink BA, et al. Nature. 2020. PMID: 31942075
3. Drug repositioning in sarcomas and other rare tumors. Lee ATJ, Huang PH, Pollack SM, Jones RL.EBioMedicine. 2016. PMID: 27211532
4. Phase III Soft Tissue Sarcoma Trials: Success or Failure? Lee AT, Pollack SM, Huang P, Jones RL.Curr Treat Options Oncol. 2017. PMID: 28332083
5. Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma. Ottaviano M, De Placido S, Ascierto PA.Virchows Arch. 2019. PMID: 30747264
6. B cells are associated with survival and immunotherapy response in sarcoma. Petitprez F, de Reyniès A, Keung EZ, Chen TW, Sun CM, Calderaro J, Jeng YM, Hsiao LP, Lacroix L, Bougoüin A, Moreira M, Lacroix G, Natario I, Adam J, Lucchesi C, Laizet YH, Toulmonde M, Burgess MA, Bolejack V, Reinke D, Wani KM, Wang WL, Lazar AJ, Roland CL, Wargo JA, Italiano A, Sautès-Fridman C, Tawbi HA, Fridman WH.Nature. 2020. PMID: 31942077
CCS Research Models(Cell Lines and Mouse Models)
1. Therapeutic potential of CPI-613 for targeting tumorous mitochondrial energy metabolism and inhibiting autophagy in clear cell sarcoma. Egawa Y, Saigo C, Kito Y, Moriki T, Takeuchi T.PLoS One. 2018. PMID: 29879220
2. Use of a newly established human cell line (SU-CCS-1) to demonstrate the relationship of clear cell sarcoma to malignant melanoma. Epstein AL, Martin AO, Kempson R.Cancer Res. 1984. PMID: 6362860
3. An obstructive role of NK cells on metastatic growth of clear-cell sarcoma cells in a xenoplant murine model. Hanamatsu Y, Saigo C, Kito Y, Takeuchi T.Mol Clin Oncol. 2021. PMID: 33262889
4. CD151 confers metastatic potential to clear cell sarcoma of the soft tissue in animal model. Kawashima K, Saigo C, Kito Y, Hanamatsu Y, Egawa Y, Takeuchi T.Oncol Lett. 2019. PMID: 31186687
5. Newly established clear cell sarcoma (malignant melanoma of soft parts) cell line expressing melanoma-associated Melan-A antigen and overexpressing C-MYC oncogene. Moritake H, Sugimoto T, Asada Y, Yoshida MA, Maehara Y, Epstein AL, Kuroda H.Cancer Genet Cytogenet. 2002. PMID: 12072203
6. Establishment and proteomic characterization of patient-derived clear cell sarcoma xenografts and cell lines. Sakumoto M, Oyama R, Takahashi M, Takai Y, Kito F, Shiozawa K, Qiao Z, Endo M, Yoshida A, Kawai A, Kondo T.In Vitro Cell Dev Biol Anim. 2018. PMID: 29197033
7. Modeling clear cell sarcomagenesis in the mouse: cell of origin differentiation state impacts tumor characteristics. Straessler KM, Jones KB, Hu H, Jin H, van de Rijn M, Capecchi MR.Cancer Cell. 2013. PMID: 23410975
8.The clear cell sarcoma functional genomic landscape
CCS Reviews